INS and polycystic ovary syndrome: A randomized controlled trial study investigated the metabolic and ovarian effects of rosiglitazone over 12 weeks in insulin-resistant women with PCOS, identifying that in this context, rosiglitazone promoted ovulation and decreased IR and insulinemia in a dose-dependent manner, and that circulating insulin and testosterone were decreased in women able to ovulate [229].